The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model
暂无分享,去创建一个
Y. Ahn | In-Jo Park | Y. S. Kim | Jin-Sang Yoon | S. Hwang | Hee-Yeon Jung | C. Kim | D. Jung
[1] Y. Ahn,et al. Refinement of the SWN-20 based on the Rasch rating model. , 2015, Comprehensive psychiatry.
[2] L. Pani,et al. Towards a framework for treatment effectiveness in schizophrenia , 2014, Neuropsychiatric disease and treatment.
[3] E. Alexopoulos,et al. Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia , 2014, BMC Psychiatry.
[4] Shin-Min Lee,et al. Validation of the Taiwanese Mandarin version of the Personal and Social Performance scale in a sample of 655 stable schizophrenic patients , 2013, Schizophrenia Research.
[5] Se-Won Lim,et al. Effectiveness of paliperidone extended‐release for patients with schizophrenia: focus on subjective improvement , 2013, Human psychopharmacology.
[6] D. Stull,et al. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia , 2012, Schizophrenia Research.
[7] Sung-Wan Kim,et al. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[8] Yeni Kim,et al. Exploration of the associations between neurocognitive function and neuroleptics side effects. , 2012, Journal of psychiatric research.
[9] Z. Weihua,et al. The Chinese version of the Personal and Social Performance Scale (PSP): Validity and reliability , 2011, Psychiatry Research.
[10] J. Chang,et al. The usefulness of a self-report questionnaire measuring auditory verbal hallucinations , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[11] Yeni Kim,et al. Clinician-rated functioning and patient-rated quality of life in schizophrenia: Implications of their correspondence for psychopathology and side effects , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[12] P. Jansen,et al. Systematic Evaluation of Rating Scales for Drug-Induced Parkinsonism and Recommendations for Future Research , 2010, Journal of clinical psychopharmacology.
[13] Seong-Jin Cho,et al. The model of the relationships among the predictors of quality of life in chronic stage of schizophrenia , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[14] P. Bebbington,et al. Side‐effects of antipsychotic medication and health‐related quality of life in schizophrenia , 2009, Acta psychiatrica Scandinavica. Supplementum.
[15] D. Patrick,et al. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia , 2009 .
[16] H. Nasrallah,et al. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia , 2008, Psychiatry Research.
[17] G. Juckel,et al. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia , 2008, Current opinion in psychiatry.
[18] D. Revicki,et al. Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community , 2008, Quality of Life Research.
[19] Y. Kaneda,et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia , 2008, Psychiatry and clinical neurosciences.
[20] T. Burns,et al. Social functioning as an outcome measure in schizophrenia studies , 2007, Acta psychiatrica Scandinavica.
[21] P. Haddad,et al. Adverse effects of antipsychotics as outcome measures , 2007, British Journal of Psychiatry.
[22] J. Bobes,et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study , 2007, Schizophrenia Research.
[23] Y. Kaneda,et al. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms , 2006, Human psychopharmacology.
[24] Y. Ahn,et al. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[25] Terry E. Duncan,et al. Alcohol use from ages 9 to 16: A cohort-sequential latent growth model. , 2006, Drug and alcohol dependence.
[26] N. Oldridge,et al. Psychometric Properties of an Established Heart Disease Specific Health-related Quality of Life Questionnaire for Pacemaker Patients , 2005, Quality of Life Research.
[27] M. Lambert,et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well‐being and clinical outcome in patients with schizophrenia , 2005, Acta psychiatrica Scandinavica.
[28] Peter B. Jones,et al. The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia , 2003, Acta psychiatrica Scandinavica. Supplementum.
[29] Y. Kaneda,et al. Schizophrenia Quality of Life Scale: validation of the Japanese version , 2002, Psychiatry Research.
[30] Y. Ahn,et al. Subjective emotional experience and cognitive impairment in drug-induced akathisia. , 2002, Comprehensive psychiatry.
[31] Toshiya Inada,et al. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol , 2002, Schizophrenia Research.
[32] D. Naber,et al. Subjective well-being and quality of life under atypical antipsychotic treatment , 2002, Psychopharmacology.
[33] R. P. McDonald,et al. Principles and practice in reporting structural equation analyses. , 2002, Psychological methods.
[34] H. Rüdiger,et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs , 2001, Schizophrenia Research.
[35] G. A. Marcoulides,et al. New developments and techniques in structural equation modeling , 2001 .
[36] P. Morosini,et al. Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning , 2000, Acta psychiatrica Scandinavica.
[37] D. Revicki,et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial , 1999, Quality of Life Research.
[38] J. Gerlach,et al. Subjective experience of treatment, side‐effects, mental state and quality of life in chronic schizophrenic out‐patients treated with depot neuroleptics , 1996, Acta psychiatrica Scandinavica.
[39] T. Barnes. A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.
[40] M. Krawiecka,et al. A standardized psychiatric assessment scale for rating chronic psychotic patients , 1977, Acta psychiatrica Scandinavica.
[41] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[42] 이현정,et al. Tolerability, Safety and Effectiveness of Paliperidone ER in Patients with Schizophrenia : A 24-Week Interim Analysis of the 48-Week Open-Label, Prospective, Switch Study , 2013 .
[43] J. Bobes,et al. Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. , 2011 .
[44] J. Bobes,et al. Validación de la versión española de la escala de Funcionamiento Personal y Social en pacientes ambulatorios con esquizofrenia estable o inestable , 2011 .
[45] W. Marks. Deep Brain Stimulation Management: Abnormal Involuntary Movement Scale , 2010 .
[46] 稲田 俊也. DIEPSS : a second-generation rating scale for antipsychotic-induced extrapyramidal symptoms : drug-induced extrapyramidal symptoms scale , 2009 .
[47] R. Heslegrave,et al. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation , 2004, Quality of Life Research.
[48] J. Mcardle,et al. Advanced studies of individual differences linear dynamic models for longitudinal data analysis. , 2001 .